id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-7371-0001,FDA,FDA-2025-P-7371,Suitability Petition from Argenta,Other,Petition(s),2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,,2025-12-30T00:27:10Z,,1,0,09000064b910c0db
FDA-2025-P-7371-0004,FDA,FDA-2025-P-7371,Appendix 2 - Proposed Generic Product Label (Draft),Supporting & Related Material,Background Material,2025-12-29T05:00:00Z,2025,12,,,2025-12-30T00:29:40Z,,0,0,09000064b910b342
FDA-2025-P-7371-0003,FDA,FDA-2025-P-7371,Appendix 1- Bimectin (Bimeda; ANADA 200-326) Product Label,Supporting & Related Material,Background Material,2025-12-29T05:00:00Z,2025,12,,,2025-12-30T00:29:19Z,,0,0,09000064b910b33f
FDA-2025-P-7371-0002,FDA,FDA-2025-P-7371,Acknowledgement Letter from FDA DMB to Argenta,Other,Acknowledgement Letter/Receipt,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,,2025-12-30T00:28:55Z,,0,0,09000064b910c0dc